An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2.

[1]  M. Attar,et al.  Design and Conduct Considerations for First‐in‐Human Trials , 2018, Clinical and translational science.

[2]  N. Greene,et al.  Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective , 2017, Regulatory toxicology and pharmacology : RTP.

[3]  J. Burrows,et al.  New developments in anti-malarial target candidate and product profiles , 2017, Malaria Journal.

[4]  S. Ward,et al.  A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle. , 2015, Angewandte Chemie.

[5]  David W. Gray,et al.  A novel multiple-stage antimalarial agent that inhibits protein synthesis , 2015, Nature.

[6]  H. Vosper,et al.  Patient Related Factors Affecting Adherence to Antimalarial Medication in an Urban Estate in Ghana , 2015, Malaria research and treatment.

[7]  F. Hsieh,et al.  Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment. , 2014, Toxicology and applied pharmacology.

[8]  N. White.  Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization , 2013, Antimicrobial Agents and Chemotherapy.

[9]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[10]  L. Benet,et al.  Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  D. Morton,et al.  A Strategy for Risk Management of Drug-Induced Phospholipidosis , 2009, Toxicologic pathology.

[12]  G. Kokwaro,et al.  Ongoing challenges in the management of malaria , 2009, Malaria Journal.

[13]  L. S. Fridericia.  Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken , 2009 .

[14]  L. Benet,et al.  The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation in Patients and to Designing Extended Release Dosage Forms , 2008, Pharmaceutical Research.

[15]  P. Rosenthal,et al.  A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes , 2008, PloS one.

[16]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .

[17]  R S Reneman,et al.  An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. , 1989, Journal of pharmacological methods.